Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis
|
|
- Rodney Smith
- 6 years ago
- Views:
Transcription
1 Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis Challenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or its relation to clinical symptoms? A. Transition from relapsing-remitting to secondaryprogressive MS is infrequently accompanied by decreases in brain volume B. Irreversible axonal injury and loss may occur early in MS C. Inflammation and demyelination predominate in later stages of MS D. Axonal loss in MS is almost always accompanied by clinical symptoms
2 Challenge Question: Diagnosis and Treatment of Clinically- Isolated Syndrome (CIS) (1) Which of the following is true about the McDonald diagnostic criteria for MS? A. The McDonald criteria do not include an objective demonstration of dissemination of lesions in both time and space B. The McDonald criteria include a category for laboratorysupported MS based on cerebrospinal fluid (CSF) oligoclonal bands or elevated IgG C. Magnetic resonance imaging (MRI) criteria are incorporated in the McDonald diagnostic scheme D. The McDonald criteria do not include possible MS Challenge Question: Diagnosis and Treatment of CIS (2) Which of the following is NOT correct concerning pharmacologic treatment of MS? A. Clinical trials to date suggest clinical outcomes are similar with delayed versus immediate treatment of patients with CIS B. BENEFIT is the only study to date showing an effect of treatment on delaying disability progression in the CIS patient population C. In PreCISe, glatiramer acetate reduced risk of clinicallydefinite MS by 45% versus placebo in CIS patients D. The safety/tolerability of interferons (IFNs) in CIS patients is consistent with the profile previously observed in patients with relapsing forms of MS
3 Challenge Question: Tolerability and Adherence Strategies Which of the following is true concerning tolerability/adherence of disease-modifying drugs (DMDs) in MS? A. Use of analgesics and dose titration schedules have been shown to improve adherence to IFN beta-1b B. Adherence is highest when patients choose their own treatment without physician guidance C. Warming the medication has no impact on injection site reactions D. Autoinjectors are not useful with MS therapies Learning Objectives Describe the value of early intervention in slowing the progression of or conversion to MS Summarize recent clinical trial data with respect to early intervention and clinical outcomes in CIS/MS List approved MS DMDs and their indications Assess the advantages and disadvantages of MS treatments with respect to their efficacy, safety, and tolerability Define nursing and physician interventions to increase the likelihood of initiating and continuing effective, safe, and tolerable MS therapy for patients with new-onset CIS/MS
4 Performance Goal Counsel patients about the importance of adherence for assuring the best outcomes with MS therapies Faculty Fred D Lublin, MD [chair] Saunders Family Professor of Neurology Corinne Goldsmith Dickinson Center for Multiple Sclerosis Mount Sinai School of Medicine New York, New York Christopher Hughes, MD, PhD Center for Neurosciences, Orthopedics and Spine Dakota Dunes, South Dakota Amy Perrin Ross, APN, MSN, CNRN, MSCN Neuroscience Program Coordinator Loyola University Medical Center Maywood, Illinois
5 Part 1 The Pathology of MS: Demyelination and Axonal Loss Occur Early and Lead to Permanent Disability Christopher Hughes, MD, PhD Center for Neurosciences, Orthopedics and Spine Dakota Dunes, South Dakota Natural History of MS Measures of brain volume Relapses and impairment MRI burden of disease MRI activity Secondary-Progressive Preclinical Relapsing-Remitting Time NEUROSCIENTIST by Trapp BD et al. Copyright 1999 by Sage Publications Inc. Journals. Reproduced with permission of Sage Publications Inc. Journals in the format electronic usage via Copyright Clearance Center. Adapted from Trapp BD et al. Neuroscientist. 1999;5:48-57.
6 Nerve Damage and Myelin Loss Exposed axons may be severed This leads to permanent loss of axons (reduced N-acetyl aspartate) Compensation occurs but is eventually exhausted This eventually leads to permanent loss of function Early treatment could prevent this cascade NEUROSCIENTIST by Trapp BD et al. Copyright 1999 by Sage Publications Inc. Journals. Reproduced with permission of Sage Publications Inc. Journals in the format electronic usage via Copyright Clearance Center. Adapted from Trapp BD et al. Neuroscientist. 1999;5: MS Clinical Trials Relapsing-remitting MS trials showed greater therapeutic benefits than secondary-progressive MS trials = Clinical trials A = Trials in CIS with IM or SC IFN beta-1a, IFN beta-1b 1-3 B = Pivotal trials in relapsing-remitting MS with IM or SC IFN beta-1a, IFN beta-1b, glatiramer acetate 4-7 C = European secondary-progressive trial with IFN beta-1b 8 D = Secondary-progressive trials with IM or SC IFN beta-1a 9,10 E = North American secondary-progressive trial with IFN beta-1b 11 A Relapsing-remitting to secondary-progressive B Relapsing-Remitting C D E Secondary-Progressive Disability threshold Disease stage Time The longer the delay in treatment, the less effective IFNs and glatiramer acetate seem to be. Secondary-progressive MS is the ultimate delay in treatment. 1. Jacobs LD et al. N EnglJ Med.2000;343: Comi G et al. Lancet. 2001;357: Kappos L et al. Neurology. 2006;67: Jacobs LD et al. Ann Neurol. 1996;39: PRISMS Study Group. Lancet. 1998;352: IFNβ Multiple Sclerosis Study Group. Neurology. 1993;43: Johnson KP et al. Neurology. 1995;45: European Study Group on Interferon Beta-1b in Secondary Progressive MS. Lancet. 1998;352: Cohen JA et al. Neurology. 2002;59: Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Neurology. 2001;56: North American Study Group on Interferon Beta-1b in Secondary Progressive MS. Neurology. 2004;63:
7 Prognosis of Disability 50% of all patients will need assistance in walking within 15 y of the onset of MS 1 3 The exacerbation rate early in the disease course predicts the future progression rate and disability status. According to Weinshenker et al, the median time to reach Expanded Disability Status Scale (EDSS) 6.0 is: <7 y in patients who had 5 attacks in the first y 13 y in those who had 2 4 attacks in the first y 18 y in those who had <2 attacks in the first y Early activity late degeneration (Disconnect) 1. Weinshenker BG et al. Brain. 1989;112 (Pt 1): Weinshenker BG et al. Brain. 1989;112 (Pt 6): Weinshenker BG et al. Brain. 1991;114 (Pt 2): Clinical Symptoms Underestimate Disease Activity MS may appear to be silent (with no new or worsening visible signs or symptoms) while it is active Silent damage to axons may lead to permanent disability later on Starting effective treatment early may help slow the accumulation of damage Today s axonal loss, tomorrow s clinical symptoms Time Clinical Clinical Clinical symptoms symptoms symptoms Axonal loss Axonal loss Axonal loss Coyle PK, Hartung H-P. Mult Scler. 2002;8:2-9. Narayanan S, et al. J Neurol.2001;248: Dalton CM et al. J Neurol Neurosurg Psychiatry. 2002;73:
8 Conclusions Multiple sclerosis causes both demyelination and neuronal loss Much of the MS disease activity is silent but progressive As the disease progresses, inflammation diminishes and neuronal dropout accelerates Early use of DMDs gives the best chance of altering the course of MS Rechallenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or its relation to clinical symptoms? A. Transition from relapsing-remitting to secondaryprogressive MS is infrequently accompanied by decreases in brain volume B. Irreversible axonal injury and loss may occur early in MS C. Inflammation and demyelination predominate in later stages of MS D. Axonal loss in MS is almost always accompanied by clinical symptoms
9 Part 2 Diagnosing and Treating Clinically Isolated Syndrome (CIS) Fred D Lublin, MD Saunders Family Professor of Neurology Corinne Goldsmith Dickinson Center for Multiple Sclerosis Mount Sinai School of Medicine New York, New York Definition of CIS A first neurologic episode, lasting at least 24 hours, which is caused by inflammation/demyelination in one or more sites in the CNS National MS Society Information Sourcebook.
10 Differential Diagnosis of CIS Stroke/transient ischemic attack (TIA) Neurosyphilis Vasculitis Sjögren s disease Systemic lupus erythematosus (SLE) Neurosarcoidosis Progressive multifocal leukoencephalopathy (PML) Lyme disease McDonald MS Diagnostic Criteria Objective demonstration of dissemination of lesions in both time and space remains essential Neurologic examination MRI and/or evoked potentials MRI is integrated with clinical and other para-clinical diagnostic methods Diagnostic evaluation outcome MS Possible MS Not MS McDonald WI et al. Ann Neurol. 2001;50:
11 MRI Criteria for Dissemination in Space and Dissemination in Time for MS McDonald Criteria 2005 Revision Dissemination in Space 3 of the following: 9 T2 lesions or 1 gadolinium (Gd)- enhancing lesion 3 periventricular lesions 1 juxtacortical lesion 1 posterior fossa lesion or spinal-cord lesion A spinal-cord lesion can replace an infratentorial lesion Any number of spinal-cord lesions can be included in total lesion count Dissemination in Time A Gd-enhancing lesion 3 months after CIS onset A new T2 lesion with reference to a baseline scan obtained 30 d after CIS onset Polman CH et al. Ann Neurol. 2005;58: Available for download at Initial CIS Studies CHAMPS (The Controlled High Risk Avonex MultiPle Sclerosis) Trial Primary end point: Time to dx of clinically definite multiple sclerosis (CDMS), defined by the appearance of new neurologic or ophthalmologic events or progressive neurologic deterioration (>1.5 in EDSS score) with sxs persisting for at least 48 h Compared with placebo, IFN beta-1a IM reduced the 3-y probability of developing CDMS by 44% (P=.002) ETOMS (Early Treatment Of Multiple Sclerosis) Trial Primary end point: Time to dx of CDMS, defined by the appearance of new neurologic events (2 neurological events in the CNS separated in time and location) The time 30% converted to clinically definite MS was 569 d for IFN beta-1a SC vs 252 d for placebo (P=.034) Beck RW et al. Am J Ophthalmol. 2001;131: Comi G et al. Lancet. 2001;357: Galetta SL. J Neuroophthalmol. 2001;21:
12 ETOMS: Delayed Progression to CDMS Proportion Without Confirmed CDMS IFN beta-1a SC Placebo Median time to second relapse in 30% pts 569 d (IFN beta-1a) vs 252 d (placebo) HR=0.65 (95% CI: ) P=.034 Time Since Randomization (d) LANCET by Comi G. Copyright 2001 by Elsevier Health Science Journals. Reproduced with permission of Elsevier Health Science Journals in the format electronic usage via Copyright Clearance Center. Comi G et al. Lancet. 2001;357: CHAMPS: Delayed Progression to CDMS Clinically Definite MS (%) Rate ratio=0.56 (95% CI: ) Log-rank P= Months Placebo IFN beta-1a IM NEW ENGLAND JOURNAL OF MEDICINE by Jacobs LD et al. Copyright 2000 by Massachusetts Medical Society. Reproduced with permission of Massachusetts Medical Society in the format electronic usage via Copyright Clearance Center. Jacobs LD et al. N Engl J Med. 2000;343:
13 Recent CIS Studies BENEFIT (BEtaseron in Newly Emerging MS For Initial Treatment) Primary end point: Time to dx of MS using the McDonald Criteria; Time to dx of CDMS using the Poser criteria PreCISe (early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis [CDMS] in subjects presenting with a Clinically Isolated Syndrome) Primary end point: Risk of conversion to CDMS using Poser criteria Kappos L et al. Neurology. 2006;67: Comi G. Late-Breaking Session American Academy of Neurology, Platform Presentation. April 18, 2008;Chicago, Ill. BENEFIT Trial BEtaseron in Newly Emerging Multiple Sclerosis For Initial Treatment A 96-wk, double-blind, placebo-controlled, randomized, phase 3 study of IFN beta-1b, 250 mcg every other day SC, vs placebo in CIS patients. Prospectively planned analysis at 3 y post randomization and 2-y follow-up (5 years post randomization) February 2002 to ongoing 20 countries, 98 study sites 487 patients randomized 392 patients completed y 3 Kappos L, et al. Neurology. 2006;67:
14 IFN Beta-1b Reduces the Rate of Conversion to McDonald MS Placebo 85% McDonald MS (%) IFN beta-1b 69% P<.0001, 46% reduction for IFN beta-1b vs placebo (proportional hazards regression) NEUROLOGY by Kappos L et al. Copyright 2006 by Lippincott Williams & Wilkins, Inc. - Journals. Reproduced with permission of Lippincott Williams & Wilkins, Inc. - Journals in the format electronic usage via Copyright Clearance Center Kappos L et al. Neurology. 2006;67: Immediate IFN Beta-1b vs Placebo/IFN Beta-1b Delays the Emergence of MS /255 = 2.42-fold increase Patients Without CDMS (%) *At 25 th percentile th percentile Immediate IFN beta-1b days Placebo/ IFN beta-1b Time (y) Kappos L et al. Neurology. 2006;67:
15 Immediate IFN Beta-1b Reduced the Risk of a Second Attack by 41% at 3 Y vs Placebo/IFN Beta-1b Patients Not Converted to CDMS (%) Kappos L et al. Lancet. 2007;370: Time (y) 41% cumulative relative risk reduction at 3 y based on Hazard Ratio= % P= % Immediate IFN beta-1b Placebo/ IFN beta-1b Immediate IFN Beta-1b vs Placebo/IFN Beta-1b Reduced the Risk of Sustained Disability (1.0 EDSS Change Confirmed Over 6 Months) % cumulative relative risk reduction based on Hazard Ratio=0.6 Patients Without EDSS Progression (%) P= % 76% Immediate IFN beta-1b Placebo/ IFN beta-1b Time (y) Kappos L et al. Lancet. 2007;370:
16 PreCISe Study Study Aim: To evaluate the safety, efficacy, and tolerability of glatiramer acetate 20 mg in subjects presenting with CIS Study Design: 3-year, multi-country, multi-center (80 centers), randomized, placebo-controlled, double-blind study 481 subjects equally randomized into 2 parallel treatment groups (glatiramer acetate 20 mg/matching placebo once daily SC) Comi G. Presented at AAN 2008, April 16, 2008; Chicago Ill. LBS.003. PreCISe Primary End Point Glatiramer Acetate Reduces the Risk to CDMS Subjects with CDMS (%) Risk Reduction of 45% Hazard Ratio= 0.55 [95% CI] P= days: + 115% Placebo Glatiramer Acetate D 336 D 722 GA 20 mg n= Placebo n= Comi G. Presented at AAN 2008, April 16, 2008; Chicago IL. LBS.003.
17 Glatiramer Acetate Reduces the Proportion of Patients Who Convert to CDMS Odds Ratio 0.41 * *P<.0001 Comi G. Presented at AAN 2008, April 16, 2008 Chicago IL. LBS.003. Conclusions All three completed studies of IFN as well as the glatiramer acetate study in the CIS population have shown a statistically significant benefit 3-year BENEFIT study demonstrated that IFN-beta 1b significantly delayed disability progression from CIS Safety/tolerability of IFNs in CIS patients is consistent with the profile previously observed. Typical side effects of treatment did not have a negative impact on adherence The clinical paradigm has shifted toward earlier diagnosis and treatment (CIS population), potentially leading to better long-term outcomes
18 Rechallenge Question: Diagnosis and Treatment of CIS (1) Which of the following is true about the McDonald diagnostic criteria for MS? A. The McDonald criteria do not include an objective demonstration of dissemination of lesions in both time and space B. The McDonald criteria include a category for laboratorysupported MS based on CSF oligoclonal bands or elevated IgG C. MRI criteria are incorporated in the McDonald diagnostic scheme D. The McDonald criteria does not include possible MS Rechallenge Question: Diagnosis and Treatment of CIS (2) Which of the following is NOT correct concerning pharmacologic treatment of MS? A. Clinical trials to date suggest clinical outcomes are similar with delayed versus immediate treatment of patients with CIS B. BENEFIT is the only study to date showing an effect of treatment on delaying disability progression in the CIS patient population C. In PreCISe, glatiramer acetate reduced risk of clinicallydefinite MS by 45% versus placebo in CIS patients D. The safety/tolerability of interferons (IFNs) in CIS patients is consistent with the profile previously observed in patients with relapsing forms of MS
19 Part 3 Impact of Medication Tolerability: Recent Study Results and New Insights Into Keeping Patients on Medication Amy Perrin Ross, APN, MSN, CNRN, MSCN Neuroscience Program Coordinator Loyola University Medical Center Maywood, Illinois Treatment Options for MS Nonproprietary drug name Brand name Dosing regimen IFN beta-1a Avonex 30 mcg IM once weekly IFN beta-1a Rebif 22 or 44 mcg SC 3 times weekly IFN beta-1b Betaseron 0.25 mg SC every other day Glatiramer acetate Copaxone 20 mg SC once daily Natalizumab Tysabri 300 mg IV every 4 weeks Mitoxantrone Novantrone 12 mg/m 2 IV every 3 months Indications Relapsing forms of MS; first clinical episode and MRI consistent w/ MS Relapsing forms of MS Relapsing forms of MS; first clinical episode and MRI consistent w/ MS Relapsing forms of MS Relapsing forms of MS* Secondary progressive, progressive relapsing, or worsening relapsing-remitting MS *Generally recommended for patients who have had inadequate response to, or are unable to tolerate other MS therapies.
20 Patient s Perception of How Treatment Choice Was Made Number % % 2181 Total Starts Percent of Total % % % % My doctor made the decision My doctor discussed this treatment and asked for my agreement My doctor discussed all therapies and recommended this treatment I requested this treatment as a result of my own research My doctor asked me to pick one 0.0 Data on file. Teva Pharmaceuticals; How Treatment Choice Was Made: Effect on Discontinuance Number of patients % % 181 My doctor made the decision Total Starts 90-Day Stops 90-Day Discontinuance Rate % My doctor discussed treatment and asked for my agreement 6.7% My doctor discussed all therapies and recommended this treatment I requested this treatment as a result of my own research 7.1% 7.5% My doctor asked me to pick one Data on file. Teva Pharmaceuticals; 2008.
21 Safety and Tolerability of DMDs in MS DMD classes have different safety and tolerability profiles IFN beta-1a/1b: flu-like symptoms, injection-site reactions, headache, elevated liver enzymes* Glatiramer acetate: injection-site reactions, dyspnea, immediate post-injection reaction* Natalizumab: PML Mitoxantrone: cardiotoxicity, secondary leukemia *Several comparative trials have been conducted between drugs from these classes. The REGARD trial showed that SC IFN beta-1a was less well tolerated than glatiramer acetate. In the BEYOND trial comparing IFN beta-1b 500 mcg, IFN beta-1b 250 mcg, and glatiramer acetate, the rank order of increasing tolerability and adherence was IFN beta-1b 500 mcg, glatiramer acetate 20 mg, and IFN beta-1b 250 mcg. Coyle P. Presented at: ECTRIMS, October 14, 2007; Prague, Czech Rep. Cited in Multiple Sclerosis. 2007;13(suppl 2):S270. Press release available at Studies Comparing Tolerability of IFN Beta-1b and Beta-1a (SC) COMFORT: injection-site pain was lower with IFN beta-1b vs IFN beta-1a (1.5 vs 7.1;P=.0018) and more pts had injections without reactions (71% vs 47%; P<.0001) 1,2 BRIGHT: more pts using autoinjectors were pain-free immediately (17% vs 5%), as well as 30 min (40% vs 16%) and 60 min (55% vs 31%) following injection of IFN beta-1b vs IFN beta-1a SC 3 CRISP: more pts had pain-free injections with IFN beta-1b vs IFN beta-1a (47% vs 27%); the mean pain severity score was lower immediately (1.0 vs 3.1), as well as 10 min (0.4 vs 1.7), and 60 min (0.3 vs 1.5) following injection 4 1. Hunter SF, et al. 18th annual meeting of the Consortium of Multiple Sclerosis Centers; June 2-6, 2004; Toronto, Canada. 2. Baum K, et al. 20th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 6-19, 2004; Vienna, Austria. 3. Baum K et al. Multiple Sclerosis. 2007;13: Harris C et al. Int J MS Care. 2005/2006;7:
22 Optimizing Tolerability and Adherence of IFN Treatment: We re Doing Better Now Slower dose titration and use of NSAIDs/analgesics Higher adherence in an IFN beta-1b trial (BENEFIT) using analgesics/slow titration vs pivotal trials that did not (93.6% vs 82.5%) 1,2 Patient support programs A nursing support program increased 1-y adherence to IFN beta-1b vs historical rates (~90% vs ~70%) 3 Autoinjectors 1. Kappos L et al. Neurology. 2001;57: Kappos L et al. Neurology. 2006;67: Piccone MA et al. 17th annual meeting of the Consortium of Multiple Sclerosis Centers; May28-June 1, 2003; San Diego, CA. Promoting Adherence: Importance of the Multidisciplinary Team Approach Physical Therapist Primary Care Physician Psychiatrist Occupational Therapist Orthopedist Nurse/APN Patient Vocational Counselor Neurologist Physiatrist Psychologist/ Neuropsychologist Social Worker Urologist Speech Pathologist Courtesy of Amy Perrin Ross, APN, MSN, CNRN, MSCN.
23 Fostering Adherence Establish a sense of realistic hope and trust Educate, educate, educate Insist that family member be present for teaching sessions Set realistic expectations Ask to see injection sites at patient visits Re-evaluate injection technique annually or if patient relates problems Maintain role of advocate Courtesy of Amy Perrin Ross, APN, MSN, CNRN, MSCN. Strategies to Address Barriers Medication specifics Set realistic expectations Discuss dosing and consistent administration Address side effects Patient/caregiver issues Identify information gaps, provide education Assess patient s financial status; support wherever possible with resources Courtesy of Amy Perrin Ross, APN, MSN, CNRN, MSCN.
24 Management of Local Injection Site Reactions Warm mixed medications to room or body temperature Warm or ice site for s before injection Inject immediatly after a shower Aerosolized ethyl chloride Local anesthetics (EMLA, Oragel, Lidoderm ) Bayas A, Rieckmann P. Drug Saf. 2000;22: Walther EU, Hohlfeld R. Neurology. 1999;53: Munschauer FE 3rd, Kinkel RP. Clin Ther. 1997;19: Injection Mechanics Consider autoinjectors Modify needle length for body mass index Avoid medication on needle tip Fully penetrate the skin to avoid intradermal infiltration Assure complete, vertical needle penetration into skin surface Postcare: Topical steroids for erythemia (avoid topical steroids at sites of infection or apparent abscess or necrosis) Courtesy of Amy Perrin Ross, APN, MSN, CNRN, MSCN.
25 Who Can Help? Neurologist Nurse Company-sponsored support Pathways ( ) Shared Solutions ( ) Lifelines ( ) MS ActiveSource ( ) Conclusions IFNs are better tolerated now than in the past Nurse Support Programs Dose escalation NSAID use Head-to-head studies show different tolerability profiles for IFN beta-1b, glatiramer acetate, and IFN beta-1a, which may affect patient adherence Given the importance of DMD use early in the course of MS, addressing tolerability and improving adherence is vital to controlling the disease Interdisciplinary interventions and nursing support can help overcome barriers to and improve adherence
26 Rechallenge Question: Tolerability and Adherence Strategies Which of the following is true concerning tolerability/adherence of disease-modifying drugs in MS? A. Use of analgesics and dose titration schedules have been shown to improve adherence to IFN beta-1b B. Adherence is highest when patients choose their own treatment without physician guidance C. Warming the medication has no impact on injection site reactions D. Autoinjectors are not useful with MS therapies Thank You
There are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 COPAXONE 20 mg/ml, solution for injection, pre-filled syringe B/28 (CIP code: 363 840-1) Applicant: SANOFI-AVENTIS
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationMedication Prior Authorization Form
(Orelizumab) Policy Number: 1073 Policy History Approve Date: 05/19/2017 Effective Date: 05/19/2017 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for
More informationAubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.PHAR.256 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.CPA.331 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationS.E.A.R.C.H. SM Patient Workbook
S.E.A.R.C.H. SM Patient Workbook How to S.E.A.R.C.H. SM for the Right MS Therapy For You! What is S.E.A.R.C.H. SM? The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by
More informationEvidence-Based Medicine What it Is. Critical Analysis of Clinical Trials Assessing Therapeutic Value
Critical Analysis of Clinical Trials Assessing Therapeutic Value Douglas S. Goodin, M.D. Professor of Neurology, UCSF Any astronomer can predict just where every star will be at half past eleven tonight.
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationAntibody therapy of multiple sclerosis Prof. Alastair Compston Dr. Alasdair Coles
Antibody therapy of multiple sclerosis & Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, U.K. 1 The story of multiple sclerosis: 1838-1993 2 The symptoms of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 7/2018 Origination: 8/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Lemtrada
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationClinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationIR Thematic Call on Multiple Sclerosis
Teresa, Multiple Sclerosis, United States IR Thematic Call on Multiple Sclerosis October 3 rd, 2013 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationSESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY
SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY Bruno C. Musch, MD PhD Baveno, Italy November 30th, 2013 DISCLOSURE OF INTEREST Dr.Musch is currently Medical Director in GENENTECH/Roche,
More information2018 ECTRIMS Data Review Call. October 2018
2018 ECTRIMS Data Review Call October 2018 TG Therapeutics Michael S. Weiss, CEO Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private
More informationClinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 04.01.17 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. Multiple Sclerosis Agents Ampyra Aubagio Avonex Betaseron Copaxone Extavia Gilenya Glatopa Plegridy Rebif Tysabri
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationRESEARCH/CLINICAL UPDATE
National Multiple Sclerosis Society 733 Third Avenue New York, New York 10017-3288 Tel +1 212.986.3240 Fax +1 212.986.7981 E-mail nat@nmss.org nationalmssociety.org October 30, 2007 RESEARCH/CLINICAL UPDATE
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple
More informationThe MS Disease- Modifying Medications. General information
The MS Disease- Modifying Medications General information Current as of April 2013. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationMycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study
Received: 20.6.2010 Accepted: 5.8.2010 Original Article Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study Masoud
More informationDisease modifying therapies in multiple sclerosis
Special Article Disease modifying therapies in multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More informationMultiple Sclerosis Agents
Multiple Sclerosis Agents Policy Number: 5.01.614 Last Review: 09/2018 Origination: 07/2014 Next Review: 09/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMultiple sclerosis (MS) is a chronic, unpredictable
Prescription Utilization by Multiple Sclerosis Patients in the United States Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Stacey Ruf, PhD; and John A. Szychowski, AAS, BS Multiple sclerosis
More informationDisclosures and Acknowledgments
214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationThe last decade has witnessed the introduction of a series of disease-modifying agents as
National Multiple Sclerosis Society 733 Third Avenue New York, NY 10017-3288 Expert Opinion Paper Treatment Recommendations for Physicians Changing Therapy in Relapsing Multiple Sclerosis: Considerations
More informationMS Injectable Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: MS Injectable Drugs Page: 1 of 5 Last Review Date: November 30, 2018 MS Injectable Drugs Description
More informationHelen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester
Helen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester helen.pervanas@mcphs.edu Objectives Describe the pathophysiology, diagnosis and prognosis of MS Discuss disease
More informationEconomic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event
2005; 11: 542 /551 www.multiplesclerosisjournal.com Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event Michael Iskedjian*,1, John H Walker 1,2, Trevor
More informationTHE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES
THE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES Brief Overview Scott Newsome It is extremely important for clinicians treating
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B016 Page: 1 of 4 and Therapeutics Quality PRODUCT APPLICATIO: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne
More informationFrancesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, and Paolo Gallo. 1. Introduction. 2. Materials and Methods
Multiple Sclerosis International Volume 2015, Article ID 369348, 5 pages http://dx.doi.org/10.1155/2015/369348 Clinical Study Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression
More informationDrug development and evaluation with small clinical Trials from the regulatory point of view
Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency
More informationExtending Our Leadership Position in Multiple Sclerosis. December 12, 2018
Extending Our Leadership Position in Multiple Sclerosis December 12, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: our strategy
More informationLong-term follow up of glatiramer acetate compassionate use in Belgium
Acta neurol. belg., 2005, 105, 81-85 Long-term follow up of glatiramer acetate compassionate use in Belgium C. J. M. SINDIC 1 *, (and in order of the number of included patients) : P. SEELDRAYERS 2, L.
More informationThe Latest Therapies for MS: Weighing Respective Benefits and Risks
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/frontlines-multiple-sclerosis/the-latest-therapies-for-ms-weighingrespective-benefits-and-risks/9639/
More informationMS: Principles of Management
Treatment t Optimization i in MS MS: Principles of Management What Is Lost Is Not Regained Delay progression to disability Cognitive and physical disability Reduce frequency and severity of relapses Treat
More informationMAY 2017 RESEARCH U P D A T E
MAY 2017 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Michelle Fabian, MD and Stephen Krieger, MD Includes additional material by Margaret M. McCormick, RN, BSN, MSCN Reviewed
More informationMAY 2018 RESEARCH U P D A T E
MAY 2018 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Tom Garry with Stephen Krieger, MD and Michelle Fabian, MD Reviewed by Jack Burks, MD Edited by Susan Courtney The 2018
More informationREVIEW ARTICLE. Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis. (MS) is a multifocal, demyelinating disease
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis A Systematic Review REVIEW ARTICLE Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD Background: Within the past 10
More informationMultiple Sclerosis International Federation December 2018
MSIF WHO EML APPLICATION Multiple Sclerosis Disease-Modifying Therapies 1. Summary statement of the proposal for inclusion In 2015, an application for widening the indication of azathioprine to cover multiple
More informationApproved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy. Date approved: 06/21/17
Integrated Healthcare Services and Criteria Document: Reference #: PC/B016 Page: 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationJNNP Online First, published on December 30, 2016 as /jnnp Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jnnp-2016-314843). For numbered affiliations see end of article. Correspondence to Professor
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationSupplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values
Supplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Detailed Input Tables Table A.1: Annual Probability
More informationDirucotide (MBP8298) for the treatment of multiple sclerosis
DRUG EVALUATION Dirucotide (MBP8298) for the treatment of multiple sclerosis Clyde Markowitz University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA Tel.: +1
More informationBarbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Barbara Cadario GLATIRAMER
Volume 29 (3) 2009 Editor: Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Contents - Glatiramer Barbara Cadario Chairman, Medical Review Laird Birmingham, M.D., M.H.Sc., F.R.C.P.(C) SYNONYM: Copolymer 1
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More informationOptions for Wheeled Mobility Resource Detectives Program Achievements MSAA. Summer Research UPDATE
Options for Wheeled Mobility Resource Detectives Program Achievements MSAA Summer 2009 MS Research UPDATE 2009 Volunteering Opportunities from MSAA Volunteering with MSAA offers multiple opportunities
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationThe Medical Letter. on Drugs and Therapeutics. Volume 58 June 6, Drugs for Multiple Sclerosis... p 71. Important Copyright Message
The Medical Letter on Drugs and Therapeutics Volume 58 ISSUE ISSUE No. 1433 1496 Volume 56 IN THIS ISSUE Drugs for Multiple Sclerosis... p 71 Important Copyright Message FORWARDING OR COPYING IS A VIOLATION
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.45 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationResearch. highlights. Historic Survey of MS. Research Progress. Searching for MS Therapies Timeline of MS. Research Progress
A report of research progress in MS Research highlights Special Issue Historic Survey of MS Research Progress In 1945, a small classified ad appeared in The New York Times: Multiple sclerosis. Will anyone
More informationECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
EAN GUIDELINES/CME ARTICLE ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X. Montalban a, R. Gold b, A. J. Thompson c, S. Otero-Romero a,d, M. P. Amato e, D. Chandraratna
More informationDisease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value
Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Response to Public Comments on Draft Evidence Report January 26, 2017 Institute
More informationEvidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal
Evidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal Title: Fingolimod for the treatment of relapsing remitting
More informationInternational Progressive Multiple Sclerosis Collaborative : Update on Research Strategy
International Progressive Multiple Sclerosis Collaborative : Update on Research Strategy Increasing disability Increasing disability Progressive Forms of MS Many MS patients begin with a relapsing form
More informationAdherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
ORIGINAL RESEARCH Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience Tatiana de Melo Gomes de Oliveira 1 Ana Patricia Peres Fiore 2 Yára Dadalti Fragoso 2 1 TEVA
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationPrior Authorization Form
5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationUnified understanding of MS disease is required for drug development. National Multiple Sclerosis Society, 733 Third Avenue, New York, NY USA 2
COMMENT Unified understanding of MS disease is required for drug development Timothy Coetzee 1 and Alan J Thompson 2 1 National Multiple Sclerosis Society, 733 Third Avenue, New York, NY 10017 USA 2 Faculty
More informationThe quality of reports of randomized trials in multiple sclerosis: a review
444327MSJ18610.1177/1352458512444327Signori et al.multiple Sclerosis Journal 2012 Topical Review MULTIPLE SCLEROSIS JOURNAL MSJ The quality of reports of randomized trials in multiple sclerosis: a review
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. September 2012 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationTodd Williamson VP US Medical Affairs, Data Generation & Observational Studies Bayer U.S. LLC
Bayer wanted to ask why Betaseron is being included as one of the comparative agents for secondary progressive MS. Within the US Betaseron is not indicated for secondary progressive MS with minimal clinical
More informationMedia Release. Basel, 14 June 2018
Media Release Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive
More informationCost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M
Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M Record Status This is a critical abstract of an economic
More informationReview of week-24 results
Review of week-24 results GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of in patients with relapsing remitting
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-7385407:2.0 Name of Sponsor/Company Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name
More information